Amerongen72 and colleagues found that the PRAME and CTCFL TCR‐T cells demonstrated potent and specific antitumor reactivity both in vitro and in vivo, the identified PRAME and CTCFL TCRs are promising candidates for the treatment of patients with ovarian cancer. This evidence concerns the gene CTCFL and ovarian carcinoma.